. 2023 Jul 9;149(11):971–977. doi: 10.1001/jamaoto.2023.1937

Table 2. Per-Test Performance Metrics for the Diagnosis and Surveillance Cohorts.

TTMV-HPV DNA test result	Diagnosis cohort (n = 163)		Surveillance cohort (n = 591)		Predictive value (95% CI), %
TTMV-HPV DNA test result	HPV-associated OPSCC	HPV-negative OPSCC	Recurrence	Disease free	Predictive value (95% CI), %
Positive, No.	139	0	38	0	100 (90.7-100)^a
Negative, No.	13	11	5	548	99.1 (97.9-99.7)^b
Sensitivity (95% CI), %	91.5 (85.8-95.4)	NA	88.4 (74.9-96.1)	NA	NA
Specificity (95% CI), %	NA	100 (71.5-100)	NA	100 (99.3-100)	NA

Abbreviations: NA, not applicable; HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma; TTMV-HPV DNA, tumor tissue–modified human papillomavirus DNA.

^{^a}

Positive predictive value.

^{^b}

Negative predictive value.